MARKET

THTX

THTX

Theratechnologies Inc
NASDAQ
1.580
-0.040
-2.47%
After Hours: 1.653 +0.073 +4.65% 19:56 03/21 EDT
OPEN
1.615
PREV CLOSE
1.620
HIGH
1.660
LOW
1.540
VOLUME
142.10K
TURNOVER
--
52 WEEK HIGH
2.180
52 WEEK LOW
1.080
MARKET CAP
72.65M
P/E (TTM)
-9.3880
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at THTX last week (0310-0314)?
Weekly Report · 4d ago
Stocks in play: Theratechnologies Inc.
Barchart · 03/12 10:19
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Barchart · 03/12 06:30
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
Barchart · 03/12 06:30
Weekly Report: what happened at THTX last week (0303-0307)?
Weekly Report · 03/10 12:31
JonesTrading Reaffirms Their Hold Rating on Theratechnologies (THTX)
TipRanks · 03/05 19:36
Weekly Report: what happened at THTX last week (0224-0228)?
Weekly Report · 03/03 12:29
Theratechnologies Reports Strong Fiscal 2024 Performance
TipRanks · 02/27 04:05
More
About THTX
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Webull offers Theratechnologies Inc stock information, including NASDAQ: THTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading THTX stock methods without spending real money on the virtual paper trading platform.